FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): December 15, 2021

BDPT_8KIMG1.JPG

BIOADAPTIVES, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware

 

000-54949

 

46-2592228

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.) 

 

2620 Regatta Drive, Suite 102

Las Vegas, Nevada 89128

(Address of Principal Executive Office) (Zip Code)

 

(702) 659-8829

Registrant's telephone number, including area code:

 

N/A

(former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 7.01 Regulation FD Disclosure

 

The Company issued a press release on December 15, 2021, announcing its marketing agreement with Acoustic Innovations LLC. The agreement provides the Company with licensing and other distribution rights with respect to the LungFlute™ medical device, including for the development of its LungArmor™ packaging combination. Additional information is available on the Company’s website at shopbioadaptives.com and the sister site at medicalflute.com.

 

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise be subject to the liabilities of that section, nor is it incorporated by reference into any filing of the Company, under the Securities Act of 1933, or the Securities Exchange Act of 1934, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

ITEM 9.01 EXHIBITS

 

9.01(d)

 

Number

 

Description

Exhibit 99.1

 

December 15, 2021 Press Release

  

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

BioAdaptives, Inc.

       

December 15, 2021

/s/ Edward E. Jacobs, MD

 

 

Edward E. Jacobs, CEO

 
       

 

 

3

 

Bioadaptives (PK) (USOTC:BDPT)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Bioadaptives (PK) Charts.
Bioadaptives (PK) (USOTC:BDPT)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Bioadaptives (PK) Charts.